− Achieved Second Quarter 2022 Global Net Product Revenues of $214 Million for ONPATTRO®, GIVLAARI®, and OXLUMO® (33% Growth vs. Same Period Last Year) – − Received FDA Approval of AMVUTTRA™ (vutrisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults – − Expects to Report Topline Results from APOLLO-B Phase 3 […]
Financial
Artio Medical Welcomes Vice President of Reimbursement
Prairie Village, KS – July 28, 2022 –Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, today announced that Raymond (Chip) Richter has joined the company as Vice President of Reimbursement. Richter is a healthcare executive and leader with over two […]
Boston Scientific Announces Results for Second Quarter 2022
MARLBOROUGH, Mass., July 27, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.244 billion during the second quarter of 2022, growing 5.4 percent on a reported basis, 9.6 percent on an operational1 basis and 6.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income […]
Silk Road Medical Reports Second Quarter 2022 Financial Results
SUNNYVALE, Calif., July 26, 2022 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2022. “We achieved several important milestones in the second quarter. We expanded […]
Surmodics Reports Third Quarter Fiscal 2022 Results
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 third quarter ended June 30, 2022 and updated its financial outlook for its fiscal 2022. Summary of Third Quarter and Recent […]
iRhythm Technologies Announces the Addition of Two Executive Leaders to Advance Strategic Growth and Operational Excellence
SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the appointment of two seasoned executives to its leadership team. Brice Bobzien will join the company as the Chief Financial Officer on August 8, 2022, […]
Todd C. Villines, M.D. Joins Elucid as new Chief Medical Officer
BOSTON, July 26, 2022 /PRNewswire/ — Elucid, a novel non-invasive software company providing physicians with AI-powered imaging to characterize cardiovascular disease, is pleased to announce that Todd C. Villines, MD, is joining the company as Chief Medical Officer. Dr. Villines will be leading clinical strategy development and execution for Elucid’s commercial and in-development […]
New Zealand Endovascular Thought Leader Joins the VESTECK Scientific Advisory Board
WEST CHESTER, Pa., July 26, 2022 /PRNewswire/ — VESTECK, Inc. is pleased to announce that, international thought leader, Professor Andrew Holden has graciously agreed to join the VESTECK Scientific Advisory Board (SAB). A New Zealander, Professor Holden is currently the Director of Northern Region Interventional Radiology Service and is based at Auckland City Hospital. […]
Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management
ANN ARBOR, Mich., July 25, 2022 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the establishment of its Scientific Advisory Board (SAB). The inaugural members of the Esperion SAB represent a diverse group of internationally renowned experts who will bring a depth and breadth of basic, translational, and clinical research […]
Verve Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
CAMBRIDGE, Mass., July 25, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the closing of its previously announced upsized underwritten public offering of 9,583,334 shares of its common stock at […]



